is a treatment strategy that combines therapeutics with diagnostics. It associates both a diagnostic test that identifies patients most likely to be helped or harmed by a new medication, and targeted drug therapy based on the test results. Ga68 Dotatate (NETSPOT) and Lu177 Dotatate (Lutathera) are Theragnostic pairs.